NEW YORK – The 360Dx Top 30 jumped 11 percent in July after a 2 percent decline in June.
The Top 30 outpaced the broader market as the Dow Jones Industrial Average rose 4 percent and the Nasdaq Biotech Index increased 7 percent month over month. The Nasdaq was down 1 percent last month.
The Top 30's largest gainers were Sera Prognostics (+40 percent), CareDx (+29 percent), and NeoGenomics (+28 percent). The main decliners were DermTech (-45 percent), Natera (-5 percent), and Sophia Genetics (-4 percent).
Sera Prognostics' share price was boosted last month by the publication of data from the AVERT PRETERM trial that looked at outcomes for patients identified as high risk by Sera's PreTRM test and treated with vaginal progesterone, daily aspirin, and increased monitoring. The babies of mothers receiving that testing and treatment had an 18 percent reduction in severe morbidity and a 25 percent reduction in birth before 32 weeks.
CareDx did not have major news preceding its stock price increase last month, although on the last day of July it reported its second quarter 2024 financial results. The firm saw a 31 percent increase in revenues, beating the consensus Wall Street analyst estimate, prompting the company to raise its full-year revenue guidance.
NeoGenomics' share price saw a jump late in July after reporting its Q2 2024 financial results. Its Q2 revenues rose 12 percent year over year, beating analysts' average estimate, as the company saw its clinical services revenue rise 15 percent from Q2 2023. Clinical test volume rose 6 percent and average revenue per clinical test increased 9 percent.
Among the decliners, DermTech's stock price has continued to decline after filing for bankruptcy in June. The company is processing orders for its DermTech Melanoma test while simultaneously attempting to sell substantially all of its assets. It received notice it will be delisted from the Nasdaq and does not plan to appeal the decision.
In contrast, neither Natera nor Sophia Genetics had key news explaining their share price declines last month.
| 360Dx Top 30 | ||||
| Company | Ticker | 31-Jul-24 | 30-Jun-24 | % change |
| Abbott* | ABT | 105.94 | 103.91 | 1.95 |
| Adaptive Biotechnologies | ADPT | 4.55 | 3.62 | 25.69 |
| Becton Dickinson | BDX | 241.06 | 233.71 | 3.14 |
| Biodesix | BDSX | 1.65 | 1.53 | 7.84 |
| Bio-Rad Laboratories | BIO | 338.36 | 273.11 | 23.89 |
| Bio-Techne | TECH | 81.59 | 71.65 | 13.87 |
| CareDx | CDNA | 19.99 | 15.53 | 28.72 |
| Castle Biosciences | CSTL | 24.13 | 21.77 | 10.84 |
| Danaher | DHR | 277.08 | 249.85 | 10.90 |
| DermTech | DMTK | 0.06 | 0.11 | -45.45 |
| Exact Sciences | EXAS | 45.68 | 42.25 | 8.12 |
| Fulgent Genetics | FLGT | 23.93 | 19.62 | 21.97 |
| GeneDx | WGS | 32.72 | 26.14 | 25.17 |
| Guardant Health | GH | 35.13 | 28.88 | 21.64 |
| Hologic | HOLX | 81.61 | 74.25 | 9.91 |
| Labcorp | LH | 215.44 | 203.51 | 5.86 |
| MDxHealth | MDXH | 2.83 | 2.39 | 18.41 |
| Myriad Genetics | MYGN | 27.97 | 24.46 | 14.35 |
| Natera | NTRA | 102.39 | 108.29 | -5.45 |
| NeoGenomics | NEO | 17.73 | 13.87 | 27.83 |
| Opko Health | OPK | 1.42 | 1.25 | 13.60 |
| OraSure Technologies | OSUR | 4.48 | 4.26 | 5.16 |
| Qiagen | QGEN | 44.49 | 41.09 | 8.27 |
| Quest Diagnostics** | DGX | 142.30 | 136.88 | 3.96 |
| QuidelOrtho | QDEL | 39.29 | 33.22 | 18.27 |
| Revvity*** | RVTY | 125.61 | 104.86 | 19.79 |
| Sera Prognostics | SERA | 8.29 | 5.92 | 40.03 |
| Sophia Genetics | SOPH | 4.40 | 4.58 | -3.93 |
| Thermo Fisher Scientific | TMO | 613.34 | 553.00 | 10.91 |
| Veracyte | VCYT | 24.00 | 21.67 | 10.75 |
| 360Dx Top 30 Average | 89.58 | 80.84 | 10.81 | |
| *Abbott paid a dividend of $.55 per share on July 15. | ||||
| **Quest Diagnostics paid a dividend of $.75 per share on July 8. | ||||
| ***Revvity paid a dividend of $.07 per share on July 19. | ||||